When bound to the extracellular domain of the EGFR, cetuximab blocks endogenous ligand binding, thereby inhibiting tumor cell proliferation and promoting cancer cell apoptosis (Sobrero et al, 2008). The gene discussed is EGFR; the disease is cancer.